NanoViricidesNNVC
NNVC
About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Employees: 7
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,150% more call options, than puts
Call options by funds: $75K | Put options by funds: $6K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
13% more funds holding
Funds holding: 32 [Q3] → 36 (+4) [Q4]
4% more capital invested
Capital invested by funds: $2.01M [Q3] → $2.09M (+$74.4K) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.19% less ownership
Funds ownership: 11.35% [Q3] → 10.16% (-1.19%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NNVC.
Financial journalist opinion
Based on 8 articles about NNVC published over the past 30 days
Positive
Proactive Investors
2 days ago
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline
NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts. In a statement, the clinical-stage biotech firm highlighted to shareholders that it develops antiviral treatments, not vaccines, and sees growing demand for broad-spectrum antiviral drugs under the policy direction of US Health and Human Services Secretary Robert Kennedy.
Neutral
Accesswire
2 days ago
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its business is not affected by the tariff policies of the US government or corresponding retaliatory policies of other governments, nor is it affected by the spending cuts being implemented by the current White House administration. Therefore, the Company believes that smart financial strategists would view the longer term strong prospects of the Company (explained below) as supporting the case of NNVC as an effective hedge against the current general stock market turmoil.
Positive
Proactive Investors
1 week ago
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak
NanoViricides (NYSE-A:NNVC) believes its broad-spectrum antiviral NV-387 could provide a crucial weapon piece in the fight against the ongoing measles outbreak in the US. The company responded to a recent opinion piece by Health and Human Services Secretary Robert F.
Neutral
Accesswire
1 week ago
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".
Positive
Proactive Investors
3 weeks ago
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.
Neutral
Accesswire
3 weeks ago
NanoViricides, Inc. Has Filed its Quarterly Report
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending December 31, 2024 with the Securities and Exchange Commission (SEC) on Friday, February 14, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057825000140/nnvc-20241231x10q.htm).
Positive
Proactive Investors
4 weeks ago
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.
Neutral
Accesswire
4 weeks ago
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes.
Positive
Proactive Investors
1 month ago
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387
With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access treatment as quickly as they can secure antibiotics for a bacterial infection. “Today if a patient goes to the doctor with a viral infection, they are told to go home and relax.
Negative
Proactive Investors
1 month ago
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
Bird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as new cases are reported in both wild and domestic birds across multiple municipalities. Bird flu, or H5N1, is a type of highly pathogenic avian influenza that causes severe disease in birds and occasionally infects humans.
Charts implemented using Lightweight Charts™